Scholarlink

<p>LBSeq4Kids is a clinically validated liquid biopsy platform combining low passage whole genome sequencing (LP-WGS) for copy number alterations (CNAs) and a custom cancer targeted sequencing panel (TSP) to detect sequence variants in cell-free DNA from the aqueous humor (AH) of the eye, cerebrospinal fluid, and plasma. We present LBSeq4Kids results from a prospective cohort of 60 ocular oncology patients, including 41 with retinoblastoma (RB),13 with non-malignant RB simulating lesions and six with other intraocular malignancies. Ninety-four percent of baseline RB samples obtained at diagnosis were positive for CNAs by LP-WGS and 83% were positive for pathogenic variants by TSP analysis. All samples obtained at clinical recurrence were positive for ctDNA whereas none of the eyes in remission had a positive finding. The presence of CNAs detected by serial sampling in patients being treated for RB was correlated with clinical disease status. None of the patients with RB-simulating lesions had a positive finding by LP-WGS. The sensitivity of the assay to detect ctDNA in the setting of active RB was 98%. LBSeq4Kids represents a groundbreaking improvement for intraocular malignancies and is highly effective in informing accurate diagnosis, risk stratification, response to therapy, and surveillance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prospective implementation of an aqueous humor liquid biopsy platform informs clinical diagnosis and management of retinoblastoma and other intraocular lesions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Laura A. T. Kagami,
  • Eirini Christodoulou,
  • Venkata Yellapantula,
  • Nerea Goni,
  • David N. Buckley,
  • Brianne Brown,
  • Dolores Estrine,
  • Cindy Fong,
  • Rima Jubran,
  • Dejerianne Ostrow,
  • Mark Reid,
  • Rachana Shah,
  • Miao Sun,
  • Dong Xu,
  • Liya Xu,
  • Jaclyn A. Biegel,
  • Jesse L. Berry

摘要

LBSeq4Kids is a clinically validated liquid biopsy platform combining low passage whole genome sequencing (LP-WGS) for copy number alterations (CNAs) and a custom cancer targeted sequencing panel (TSP) to detect sequence variants in cell-free DNA from the aqueous humor (AH) of the eye, cerebrospinal fluid, and plasma. We present LBSeq4Kids results from a prospective cohort of 60 ocular oncology patients, including 41 with retinoblastoma (RB),13 with non-malignant RB simulating lesions and six with other intraocular malignancies. Ninety-four percent of baseline RB samples obtained at diagnosis were positive for CNAs by LP-WGS and 83% were positive for pathogenic variants by TSP analysis. All samples obtained at clinical recurrence were positive for ctDNA whereas none of the eyes in remission had a positive finding. The presence of CNAs detected by serial sampling in patients being treated for RB was correlated with clinical disease status. None of the patients with RB-simulating lesions had a positive finding by LP-WGS. The sensitivity of the assay to detect ctDNA in the setting of active RB was 98%. LBSeq4Kids represents a groundbreaking improvement for intraocular malignancies and is highly effective in informing accurate diagnosis, risk stratification, response to therapy, and surveillance.